COPY OF PAPERS **ORIGINALLY FILED** AUG 2 8 2002

RECEIVED

TECH CENTER 1600/2909,

Please type a plus sign (+) inside this box +

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

ender the Paperwork Reduction Act of 1995, no person		Application Number	10/053,053 10/05/653
TRANSMITT	'AL	Filing Date	01/17/2002
FORM	, e	First Named Invento	David Henry Small
(to be used for all correspondence after	r initial filing)	Group Art Unit	1642
		Examiner Name	Unassigned ***
Total Number of Pages in This Subm	ssion 81	Attorney Docket Num	ber 009621-39189
	ENCL	OSURES (che	ck all that apply)
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing Drawing Licensir Petition Provisio Change Address Termina Reques	to Convert to a nal Application of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1) PTO Form 1449 2) 10 References 3) Return Receipt Postcard
SIGNATU	IRE OF APPLI	CANT, ATTORNEY, C	DR AGENT
Firm		stration No. 34,781	,
Date 08/20/2002			
	CERTIFIC	ATE OF MAILING	
I hereby certify that this correspondence is being mail in an envelope addressed to: Commissioner	deposited with the for Patents, Wa	he United States Postal S shington, DC 20231 on the	Service with <u>sufficient postage as first</u> class his date: 08/20/2002
Typed or printed name Maxine R. S	trully		
Signature			Date 08/20/2002

Burden Hour Statement: This form is estimated to leak 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

0 0 9 6 2 1 - 3 9 1 8 9

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

the Patent Application of:

Small et al.

Group Art Unit:

TECH CENTER 1600/2900 1642

Serial No .:

10/053,653

Examiner:

Unassigned

Filed:

January 17, 2002

Atty. Dkt. No:

009621-39189

Title: METHOD FOR THE DIAGNOSIS

OF ALZHEIMER'S DISEASE AND

OTHER PRION RELATED

DISORDERS

COPY OF PAPERS ORIGINALLY FILED

Assistant Commissioner of Patents United States Patent and Trademark Office Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. §1.97-1.99, applicants and their attorneys respectfully request that the references cited on the attached Form PTO 1449 be made of record in the official United States Patent and Trademark Office file for the above-identified application.

Copies of the references are submitted herewith along with the completed form PTO-1449. The references listed on attached Form PTO-1449 were set forth in an International Search Report mailed by the European Patent Office on August 6, 2002. A copy of the International Search Report is enclosed herewith.

The citations listed on Form PTO-1449 do not constitute an admission that the references are relevant or material to the claims.

Consideration of this Supplemental Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56. The submission of references with this Information Disclosure Statement should not be construed by the Examiner that a comprehensive search through the prior art was conducted; it is requested that the Examiner make such a comprehensive search.

Each item of information contained in this Supplemental Information Disclosure Statement was cited for the first time in a communication from a foreign patent office in a Serial No. 10/053,653 Art Unit 1642 Page 2

application not more than three months prior to the filing of this statement. Consequently, no fee is due.

If any extra fees are due in connection with the submittal of this paper, the Examiner is hereby authorized to charge Deposit Account No. 03-3839.

Please address all correspondence to the correspondent address for Customer No. 26345 of Gibbons, Del Deo, Dolan, Griffinger & Vecchione. Telephone calls should be made to Livia S. Boyadjian by dialing Area Code (973) 596-4500.

Respectfully submitted,

Livia S. Boyadjian

Reg. No. 34,781

Attorney for Applicant

Gibbons, Del Deo, Dolan, Griffinger & Vecchione One Riverfront Plaza Newark, New Jersey 07102-5497

Date: August 20, 2002



Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 009621-39189	Serial No. 10/053,653	/F
	al sheets if necessary)		AUG 2 8 2	
NIB 26 2002 PS	,,	Applicant Small et al.	TECH CENTER 16	
AUG TRACEMENT		Filing Date February 21, 2002	Group Art 1642	
TRADEMEN				

U. S. PATENT DOCUMENTS

*Examiner Initial		Docu	ument	Numb	er			Date	Name	Class	Sub- class	Filing Date If Appropriate
	AA					l	<u> </u>					
	AB						<u> </u>					
	AC											
	AD											
	AE											

FOREIGN PATENT DOCUMENTS

*Examiner Initial		Doc	ument	Numb	er						Date	Name	Class
	AF	w	0	9	9	1	5	6	9	5	04/01/99	Small et al.	
	AG	w	0	0	1	7	7	3	7	0	10/18/01	Small et al.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Page, Etc.)

Saez-Valero J et al: "Altered Glycosylation of Cerebrospinal Fluid Butyrylcholinesterase in Alzheimer's Disease". Brain Research, Amsterdam, NL, vol. 889, pages 247-250, 19 January 2001. Arendt T et al: "Decreased Ratio of CSF Acetylcholinesterase to Butyrlcholinesterase Activity in Alzheimer's Disease", Lancet,
Arendt T et al: "Decreased Ratio of CSF Acetylcholinesterase to Butyrlcholinesterase Activity in Alzheimer's Disease", Lancet,
The, Lancet Limited, London, GB, vol. 1, no. 8369, January 1984.
Saez-Valero J et al: "Molecular Isoform Distribution and Glycosylation of Acetylcholinesterase Are Altered in Brain And Cerebrospinal fluid of Patients With Alzheimer's Disease", Journal of Neurochemistry, New York, NY, US, vol. 72, , pages 1600-1608, 1999.
Saez-Valero Javier et al: "Glycosylation of acetylocholinesterase as diagnostic marker for Alzheimer's disease." Lancet (North American Edition), vol. 350, no. 9082, page 929, 1997.
Saez-Valero J et al: "Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease." Journal of Neurology & Psychiatry, vol. 69, no. 5, 2000-2011, November 2000.
Szumanska G et al: "Lectin Histochemistry of Plaques and Tangles in Alzheimer's Disease". ACTA Neuropathologica, vol. 73, no. 1, pages 1-11, 1987.
Sparkman D R et al: "Paired Helical Filaments Are Not The Major Binding Sites For Wheat Germ and Dolichos-Biflorus Aggutinins in the Neurofibrillary Tangles of Alzheimer's Disease" ACTA Neuropathologica, vol. 79. no. 6 pages 640-646., 1990.
Saez-Valero Javier et al: "Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease." Journal of Alzheimer's Disease, vol. 3, no. 3, pages 323-328, June 2001.
_

Date Considered